SCHEMBL3235666

SCHEMBL3235666

CCCn1c(=O)n(Cc2cccc(Cl)c2)c(=O)c2c1nc(CC)n2C

nearest known ligand 0.58

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 2/20 0.58
POLB P06746 1/20 0.53
ALDH1A1 P00352 3/20 0.52
TSHR P16473 2/20 0.52
TP53 P04637 1/20 0.52
ALOX15 P16050 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
HPGD P15428 1/20 0.51
HIF1A Q16665 1/20 0.51
ADORA2A P29274 4/20 0.50
ADORA2B P29275 4/20 0.50
SMN1; SMN2 Q16637 2/20 0.49
HSD17B10 Q99714 1/20 0.49
MAPT P10636 1/20 0.49
ADORA1 P30542 2/20 0.48
HTT P42858 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3238173 0.88 MAPT (0.55) ADORA3POLBALDH1A1TSHRTP53
SCHEMBL3236227 0.86 MAPT (0.58) ALDH1A1TSHRTP53NPSR1HPGD
SCHEMBL3231844 0.83 ALDH1A1 (0.53) ADORA3ALDH1A1HIF1AADORA2AADORA2B
SCHEMBL3229109 0.83 ADORA2A (0.59) ADORA3POLBALDH1A1NPSR1HPGD
SCHEMBL3234639 0.83 MAPT (0.55) ADORA3POLBALDH1A1TSHRTP53
SCHEMBL3228313 0.83 TP53 (0.55) POLBTSHRTP53ALOX15NPSR1
SCHEMBL3227315 0.82 ADORA3 (0.48) ADORA3TP53ADORA2AADORA2BMAPT
SCHEMBL3221616 0.82 ADORA1 (0.55) ADORA3ALDH1A1TSHRNPSR1HPGD
SCHEMBL3224011 0.80 ADORA3 (0.60) ADORA3POLBALDH1A1TSHRNPSR1
SCHEMBL3226126 0.79 ADORA1 (0.60) ADORA3HIF1AADORA2AADORA2BADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2146996-A1 XANTHINE COMPOUNDS HAVING A POSITIVE ALLOSTERIC GABAB RECEPTOR MODULATOR EFFECT AstraZeneca AB (SE) 2010-01-27 EP claimed
US-20090023704-A1 Novel Compounds 737 ASTRAZENECA AB (SE) 2009-01-22 US claimed
WO-2008130314-A1 XANTHINE COMPOUNDS HAVING A POSITIVE ALLOSTERIC GABAB RECEPTOR MODULATOR EFFECT ASTRAZENECA AB (SE) 2008-10-30 WO claimed
EP-2146996-A1 XANTHINE COMPOUNDS HAVING A POSITIVE ALLOSTERIC GABAB RECEPTOR MODULATOR EFFECT AstraZeneca AB (SE) 2010-01-27 EP disclosed
US-20090023704-A1 Novel Compounds 737 ASTRAZENECA AB (SE) 2009-01-22 US disclosed
US-20090023704-A1 Novel Compounds 737 ASTRAZENECA AB (SE) 2009-01-22 US disclosed
US-20090023704-A1 Novel Compounds 737 ASTRAZENECA AB (SE) 2009-01-22 US disclosed
WO-2008130314-A1 XANTHINE COMPOUNDS HAVING A POSITIVE ALLOSTERIC GABAB RECEPTOR MODULATOR EFFECT ASTRAZENECA AB (SE) 2008-10-30 WO disclosed
WO-2008130314-A1 XANTHINE COMPOUNDS HAVING A POSITIVE ALLOSTERIC GABAB RECEPTOR MODULATOR EFFECT ASTRAZENECA AB (SE) 2008-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023704-A1 Novel Compounds 737 GRPR, GABRB1, GABBR1 ADORA3 177/4885POLB 4001/4885ALDH1A1 1248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.